Urodynamic Feasibility Study Utilizing the UroLift® System

NACompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 25, 2018

Primary Completion Date

April 22, 2019

Study Completion Date

November 27, 2019

Conditions
Benign Prostatic Hyperplasia
Interventions
DEVICE

UroLift

"The UroLift System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH).~During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra."

Trial Locations (1)

78705

Midtown Urology Associates, Austin

All Listed Sponsors
lead

NeoTract, Inc.

INDUSTRY

NCT04271020 - Urodynamic Feasibility Study Utilizing the UroLift® System | Biotech Hunter | Biotech Hunter